Abstract

Background: Heart-type fatty acid-binding protein (H-FABP) is a promising novel biomarker for risk stratification of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Whether disease severity in a group of patients with pre capillary pulmonary hypertension (PH) can be predicted by determination of plasma H-FABP levels remains unknown. Methods: 41 consecutive patients with a mean (±SD) age of 60.6 ± 2.1 years and severe PH were studied with a mean follow up to 541 days (95% CI: 420; 661 days). H-FABP, but also the biomarkers NT-Pro-BNP and big-endothelin (Big-ET1), were correlated to parameters derived from right sided cardiac catheterization and cardio-pulmonary exercise test. Results: At baseline H-FABP levels ranged from 620 to 15200 pg/ml (3648 ± 502 pg/ml) and were weakly but significantly correlated to VO2AT (r = –0.37, p = 0.04) and VO2 peak (r =–0.38, p = 0.03). However, invasively measured hemodynamic parameters of PH and right ventricular dysfunction did not correlate with H-FABP levels. In- terestingly, moderate to high correlations between H-FABP and NT-Pro-BNP (r = 0.51, p = 0.01) and Big-ET1 (r = 0.65, p = 0.01) and between Big-ET1 and NT-Pro-BNP (r = 0.5, p = 0.01) could be observed. In contrast to H-FABP, NT-Pro-BNP, and even more Big-ET1, showed significant correlations to different invasively measured hemodynamic parameters of the disease indicating severity and consequently prognosis of severe pre-capillary pulmonary hypertension. However, in a multivariate Cox regression analysis, PVR, mixed venous oxygen saturation and the VE/VCO2 slope (>60) as well as the heart rate recovery within one minute (HRR) but none of the biomarkers were identified as independent factors of poor prognosis. In con- trast, peak workload and mixed venous saturation were identified as risk markers in the idiopathic pulmonary arterial hypertension subgroup. Conclusions: In contrast to the predictive value of H-FABP in CTEPH H-FABP fails to be a reliable marker in PH or to be a novel predictor of mid and long term outcome. The data suggest that an increased slope of VE/VCO2 and a decreased extent of HRR within one minute represent more promising diagnostic non invasive parameters.

Highlights

  • Pulmonary arterial hypertension (PAH) is a progressive disease with poor prognosis due to fatal right heart failure

  • We investigated the Heart-type fatty acid-binding protein (H-Fatty acid-binding proteins (FABPs)) to determine whether H-FABP is an indicator of disease severity and survival in patients with various forms of chronic pre-capillary pulmonary hypertension (PH) within different stages of the disease and under different medical therapies

  • In a midterm follow up period of about two years, baseline H-FABP concentrations were not different between patients with an adverse outcome compared to those with a favourable course

Read more

Summary

Introduction

Pulmonary arterial hypertension (PAH) is a progressive disease with poor prognosis due to fatal right heart failure. It has been demonstrated that plasma BNP levels increase in correlation with the degree of right ventricular (RV) dysfunction and are well predictive for the functional status of patients with idiopathic pulmonary hypertension (IPAH) [11,12]. Heart-type fatty acid-binding protein (H-FABP) is a promising novel biomarker for risk stratification of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Whether disease severity in a group of patients with pre capillary pulmonary hypertension (PH) can be predicted by determination of plasma H-FABP levels remains unknown. In contrast to H-FABP, NT-Pro-BNP, and even more Big-ET1, showed significant correlations to different invasively measured hemodynamic parameters of the disease indicating severity and prognosis of severe pre-capillary pulmonary hypertension. The data suggest that an increased slope of VE/VCO2 and a decreased extent of HRR within one minute represent more promising diagnostic non invasive parameters

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.